Investing in Biopharma? Four things to know about industry leader Gilead Sciences
Politics & Economics

Investing in Biopharma? Four things to know about industry leader Gilead Sciences

By Marguerite Ward 1. Gilead’s numbers are looking good: The California-based biopharmaceutical company continues to see success with its HIV drugs (Stribild, Viread ect.) and Hepatitis C drugs (Sovaldi and Harvoni). Gilead’s stock is up 6.24 percent year-to-date at $100.14, swiftly outpacing the NASDAQ composite index’s 1 percent decline over the same period. Its earnings per … Continue reading